Chui Ming Gemmy Cheung, MBBS | Image Credit: Duke NUS Medical School
A recent post hoc analysis identified faricimab as exhibiting greater improvements in anatomic outcomes than aflibercept during the head-to-head testing phase of the TENAYA and LUCERNE trials in neovascular age-related macular degeneration (nAMD).
TENAYA and LUCERNE were randomized, double-masked, non-inferiority trials across 271 sites globally. Across both trials, a total of 1329 treatment-naïve patients with nAMD ≥50 years were randomized 1:1 to intravitreal faricimab 6 mg up to every 16 weeks, or aflibercept 2 mg every 8 weeks.2
In both trials, faricimab exhibited non-inferiority to aflibercept in best-corrected visual acuity (BCVA) change from baseline. Investigators determined that faricimab given at up to 16-week intervals demonstrated the…